Use of novel oral anticoagulation agents for VTE was established after a series of non-inferior trials that compared NAOCs with conventional therapy of LMWH and warfarin. The AMPLIFY trial was a randomized non-inferior trial that studied the usefulness of apixaban in preventing the recurrence of VTE after initial episode compared to conventional therapy of warfarin. The trial not only successfully established the efficacy of apixaban but also indicated its safety profile in terms of bleeding risk. Based on this trial, the 2016 CHEST guidelines for long term anticoagulation for VTE recommended NOAC over vitamin K antagonist (VKA) therapy. (all Grade 2B)
[TheChamp-Sharing style="background-color:#FFFFFF;"]Want to read more posts?